Operator

Good day, and welcome to Medicure's earnings conference call for the year ended December 2025. My name is Ali, and I will be your operator for today's call. [Operator Instructions]

Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events and expectations, which are pursuant to the safe harbor provisions of the United States Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, those described in the company's most recent annual information form and Form 20-F. [Operator Instructions] And please note, this conference call is being recorded, and today's date is April 27, 2026.

I would now like to turn the conference call over to Dr. Albert Friesen, Chief Executive Officer of Medicure Inc. Please go ahead, Dr. Friesen.

Albert Friesen
Founder, CEO & Chairman of the board

Thank you, Ali, and good morning to all on the call. We appreciate your interest and participation in today's call. Joining me today on the 2025 year-end statement call is Haaris Uddin, Medicure's Chief Financial Officer.

Net revenue was $28.9 million for the year ending December 31, 2025, compared to $21.9 million in the previous year. Net revenue was $8.5 million during the quarter compared to $5.9 million for the previous year's quarter. The company recorded a net loss for the year ending December 31 of $7.1 million or $0.68 per share compared to a net loss of $1 million for the year ending 2024. The net loss is due in large